DBX® Demineralized Bone Matrix Putty

DONATED HUMAN TISSUE

CAUTION: DEVICE IS FOR SINGLE PATIENT USE ONLY.


DESCRIPTION

DBX Demineralized Bone Matrix Putty is processed human bone that has been demineralized and combined with sodium hyaluronate, which is a naturally derived material not of animal origin that is both biocompatible and biodegradable. The combination of demineralized bone and sodium hyaluronate results in a putty-like consistency for ease and flexibility of use during surgical application.

OSTEOINDUCTIVE POTENTIAL

DBX Demineralized Bone Matrix is osteoinductive and has been shown to have osteoinductive potential in an athymic mouse model. Every lot of DBX Putty product is tested in vivo or in vitro, which has been shown to have a positive correlation with the athymic mouse model, to ensure the osteoinductive potential of the final product. Standard testing performed in vivo or in vitro must prove positive for lot release. It is unknown how the osteoinductive potential measured in vivo or in vitro, will correlate with clinical performance in human subjects.

INDICATIONS FOR USE

DBX Putty is intended for use as a Demineralized Bone Matrix for voids or gaps that are not intrinsic to the stability of the bony structure. DBX Putty is indicated for treatment of surgically created osseous defects or osseous defects created from traumatic injury.

- Mandibular reconstruction
- Repair of traumatic defects of the alveolar ridge, excluding maxillary and mandibular fracture
- Filling resection defects in benign cysts, or other osseous defects in the alveolar ridge wall
- Filling of cystic defect
- Filling of lesions or periodontal origin
- Filling of defects of endontic origin

DBX Putty can be used as an extender in the spine, pelvis, and extremities with autograft or allograft. DBX Putty can be used with bone marrow aspirate. DBX Putty is for single patient use only.

CONTRAINDICATIONS

DBX Putty is NOT intended to provide structural support of the bone during the healing process. DBX Putty is also contraindicated for incomplete skull growth.

ADVERSE EFFECTS

Possible adverse effects of using DBX Putty include, but are not limited to:
- Potential loss of contour of skull
- Infection of soft tissue and/or bone (osteomyelitis)
- Fever
- Deformity of the bone at the site
- Incomplete bone ingrowth, delayed union or non-union
- Hypercalcemia or transient hypercalcemia
- Fracture of the newly formed bone
- Disease transmission and undesirable immune response

Throughout the United States: Adverse outcomes attributable to the tissue must be promptly reported to the local representative.

CAUTIONS

Do not contaminate. Do not freeze. DBX Demineralized Bone Matrix Putty may extrude into facial soft tissue and the effect of extrusion in cranial applications, due to the lack of soft tissue, has not been investigated.

Trace amounts of Gentamicin may be present. Tissue is exposed to processing solutions that may contain dextrose and antibiotics. Trace amounts of processing solutions may remain. Caution should be exercised if the patient is allergic to any of these substances. NOTE: No β-lactam antibiotics are used during the processing of tissue in DBX Putty products.

Extensive medical screening procedures have been used in the selection of all tissue donors for MTF. Outside of the United States: Adverse outcomes attributable to the tissue must be promptly reported to your local representative.

Some tissues are treated with low-dose gamma radiation. For these tissues the container label will state, “Treated with Gamma Radiation.” Samples from each donor lot of DBX Putty were tested and showed no evidence of microbial growth, complying with the requirements of USP <71> Sterility Tests.

INSTRUCTIONS FOR USE

DBX Putty is packaged in a glass syringe and must be extruded into a sterile basin, not directly into the operative site. THE SYRINGE IS NOT AN APPLICATOR. Care should be taken to apply gentle, even force to the plunger when extruding DBX Putty from the syringe. Extreme force applied to the plunger may cause the glass syringe to break. DBX Putty can be used alone or mixed with autogenous or allograft bone (1:1 ratio by volume), or with bone marrow aspirate (2.0 mL/2.8 g of DBX Putty or 2.0 cc/2.8 cc of DBX Putty).
NOTE: This allograft has been aseptically packaged into sterilized packaging components. To make ready for use, open the package using aseptic/sterile techniques.

Instructions for Opening the Packaging:
1. Peel back lid of outer tray.
2. Pass inner tray to sterile field.
3. Peel back lid of inner tray.
4. Remove syringe from inner tray.
5. Remove protective cap from end of syringe.
6. Extrude DBX Putty into a sterile basin.
7. Shape and use DBX Putty as per surgeon’s preference.

Dispose of excess or unused tissue and all packaging that has been in contact with the tissue in accordance with recognized procedures for discarding regulated medical waste materials.

DONOR SCREENING & TESTING
Prior to donation, the donor’s medical/social history is screened for medical conditions or disease processes that would contraindicate the donation of tissue in accordance with current policies and procedures approved by the MTF Medical Board of Trustees. Donor blood samples taken at the time of recovery were tested by a facility that is CLIA certified and registered with the FDA. The donor blood samples were tested for:

- Hepatitis B surface antigen
- Hepatitis B core antibody
- Hepatitis C antibody
- HIV -1
- HIV -1 (NAT)
- HBV (NAT)
- Syphilis
- HCV (NAT)

All infectious disease tests were negative. This allograft tissue has been determined to be suitable for transplantation.

The infectious disease test results, consent, current donor medical history interview, physical assessment, available relevant medical records to include previous medical history, laboratory test results, autopsy and coroner reports, if performed, and information obtained from any source or records which may pertain to donor suitability, have been evaluated by an MTF physician and are sufficient to indicate that donor suitability criteria current at the time of procurement, have been met. This issue is suitable for transplantation. The donor suitability criteria used to screen this donor are in compliance with the FDA regulations published in 21 CFR Part 1271 Human Cells, Tissues, and Cellular and Tissue Based Products, as applicable. All procedures for donor screening, serologic and microbiologic testing meet or exceed current standards established by the American Association of Tissue Banks.

VIRAL CLEARANCE AND INACTIVATION
A panel of model potential human viruses representing various virus types, sizes, shapes and genomes were evaluated. The viral inactivation testing demonstrated suitable viral inactivation potential of the processing method for a wide spectrum of potential human viruses. The DBX Putty process further reduces the risk of viral contamination beyond donor testing and screening procedures.

PACKAGING & LABELING
DBX Putty is aseptically packaged in a sterilized syringe. The syringe containing DBX Putty is inside two plastic trays, each sealed with foil lids. The outer tray is labeled and then put in a box.

This allograft must not be used under any of the following circumstances:

- If the container seal is damaged or not intact or has any physical damage;
- If the container label or identifying bar code is severely damaged, not legible or is missing; or
- If the expiration date shown on the container label has passed.

STORAGE
Store DBX Putty at ambient temperature. No refrigeration or freezing is required. It is the responsibility of the transplant facility or clinician to maintain the tissue intended for transplantation in the appropriate recommended storage conditions prior to transplant.

PATIENT RECORD
Tissue recipient records must be maintained by the consignee and transplant facility for the purpose of tracing tissue post-transplantation. A TissueTrace® Tracking Form and peel-off stickers have been included with each package of tissue. The serial number and the tissue description have been preprinted on the peel-off stickers. Please record the patient ID, name and address of the transplant facility, allograft tissue information (using the peel-off stickers), and comments regarding the use of the tissue on the TissueTrace Tracking Form. Alternatively a system for electronic tissue information (using the peel-off stickers), and comments regarding the use of the tissue on the TissueTrace Tracking Form. Alternatively a system for electronic submission may be used and sent to MTF/TTCT@Sceris.com. Within the United States: Once completed, the bottom page of the form should be returned to MTF using the self-addressed mailer. Copies of this information should be retained by the transplant facility for future reference. Outside of the United States: Once completed, the bottom page of the form should be returned to the local allograft representative or provider. Copies of this information should be retained by the hospital for future reference.

Reference: Current MTF policies and procedures are in compliance with current FDA, AABB and other regulatory requirements.

Definitions of Label Symbols

CAUTION: Federal (US) law restricts this device to sale, distribution and use by or on the order of a physician. Please note: Human tissue for transplantation shall not be offered, distributed or dispensed for Veterinary Use.

MTF tissue forms and products are protected by one or more issued or licensed United States patents. A list of patents on available tissues and related technologies may be found on the MTF web site www.mtf.org.

DBX® is a registered trademark of MTF.

MTF/Musculoskeletal Transplant Foundation® and TissueTrace® are registered trademarks of the Musculoskeletal Transplant Foundation, Edison, NJ USA.

©2016 Musculoskeletal Transplant Foundation.

CTD: 100024